These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36037795)

  • 1. Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy.
    Vieira DB; Antel J; Peters T; Miehle K; Stumvoll M; Hebebrand J; Schlögl H
    Obes Facts; 2022; 15(5):685-693. PubMed ID: 36037795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leptin Substitution in Patients With Lipodystrophy: Neural Correlates for Long-term Success in the Normalization of Eating Behavior.
    Schlögl H; Müller K; Horstmann A; Miehle K; Püschel J; Villringer A; Pleger B; Stumvoll M; Fasshauer M
    Diabetes; 2016 Aug; 65(8):2179-86. PubMed ID: 27207511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beneficial effects of leptin substitution on impaired eating behavior in lipodystrophy are sustained beyond 150 weeks of treatment.
    Püschel J; Miehle K; Müller K; Villringer A; Stumvoll M; Fasshauer M; Schlögl H
    Cytokine; 2019 Jan; 113():400-404. PubMed ID: 30539782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
    Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
    Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facial soft tissue volume decreases during metreleptin treatment in patients with partial and generalized lipodystrophy.
    Miehle K; Stumvoll M; Fasshauer M; Hierl T
    Endocrine; 2017 Nov; 58(2):262-266. PubMed ID: 28993984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
    Grover A; Quaye E; Brychta RJ; Christensen J; Startzell MS; Meehan CA; Valencia A; Marshall B; Chen KY; Brown RJ
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4163-e4178. PubMed ID: 33890058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy.
    Chan JL; Lutz K; Cochran E; Huang W; Peters Y; Weyer C; Gorden P
    Endocr Pract; 2011; 17(6):922-32. PubMed ID: 22068254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.
    Meral R; Malandrino N; Walter M; Neidert AH; Muniyappa R; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1739-e1751. PubMed ID: 34677608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
    J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T; Cochran E; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Emergence of Appetite and Hunger Resulting in Weight Gain and Improvement of Eating Disorder Symptomatology during and after Short-Term Off-Label Metreleptin Treatment of a Patient with Anorexia Nervosa.
    Gradl-Dietsch G; Milos G; Wabitsch M; Bell R; Tschöpe F; Antel J; Hebebrand J
    Obes Facts; 2023; 16(1):99-107. PubMed ID: 36349765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity associated with metreleptin treatment in patients with obesity or lipodystrophy.
    Chan JL; Koda J; Heilig JS; Cochran EK; Gorden P; Oral EA; Brown RJ
    Clin Endocrinol (Oxf); 2016 Jul; 85(1):137-49. PubMed ID: 26589105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
    Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
    Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: clinical improvements observed in first off-label metreleptin treatment of a patient with atypical anorexia nervosa.
    Hebebrand J; Antel J; Peters T
    Eur Child Adolesc Psychiatry; 2024 Jul; 33(7):2267-2272. PubMed ID: 37874404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes.
    Vatier C; Kalbasi D; Vantyghem MC; Lascols O; Jéru I; Daguenel A; Gautier JF; Buyse M; Vigouroux C
    Orphanet J Rare Dis; 2019 Jul; 14(1):177. PubMed ID: 31300002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metreleptin Treatment in Patients with Non-HIV Associated Lipodystrophy.
    Akinci G; Akinci B
    Recent Pat Endocr Metab Immune Drug Discov; 2015; 9(2):74-8. PubMed ID: 26556498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metreleptin: first global approval.
    Chou K; Perry CM
    Drugs; 2013 Jun; 73(9):989-97. PubMed ID: 23740412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for leptin-replacement therapy for severe lipodystrophy.
    Oral EA; Chan JL
    Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Nagayama A; Ashida K; Watanabe M; Moritaka K; Sonezaki A; Kitajima Y; Takahashi H; Yoshinobu S; Iwata S; Yasuda J; Hasuzawa N; Ozono S; Motomura S; Nomura M
    Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.